- CH₣892.19m
- CH₣721.85m
- €104.17m
Ireland's Cosmo recurring revenue rises on winlevi growth, reaffirms FY guidance
Brief: Cosmo Pharmaceuticals H1 EPS EUR -0.279
Cosmo Pharma's male hair loss treatment shows sustained hair growth in year‑long study
Europe Research Roundup: Airbus ,Bechtle, Salzgitter
Europe Research Roundup: Endesa ,Cosmo Pharmaceuticals, Oxford Biomedica
Cosmo Pharmaceuticals' 2025 recurring revenue rises, proposes dividend
Brief: Cosmo Pharmaceuticals FY Operating Income EUR -3.236 Million
Europe Research Roundup: Ageas, Evotec, Sandvik
Ireland's Cosmo Pharmaceuticals misses 2025 revenue expectations
Brief: Cosmo Pharmaceuticals H1 Operating Income EUR -1.411 Million
Brief: Cosmo Pharmaceuticals H1 EPS EUR 4.705
Europe Research Roundup: BMW, Life Science REIT, SGL Carbon
Brief: Glenmark Pharmaceuticals And Cosmo Announce Signing Of Distribution And License Agreements For Winlevi In Europe, South Africa
Brief: Cosmo And Glenmark Announce The Signing Of Distribution And License Agreements For Winlevi In Europe And South Africa
Brief: Cosmo And Adalvo Sign License And Supply Agreement For Rifamycin Sv Mmx® 200Mg In Europe, APAC, MENA And Latam Regions
Brief: Cosmo Pharmaceuticals Says Termination Of Agreement For Rifamycin Sv Mmx® With Dr. Falk Pharma
Brief: Cosmo Reports H1 Pretax Profit Of 3.7 Mln EUR Vs 9.1 Mln EUR Year Ago
Europe Research Roundup: Air Liquide SA, Cosmo Pharmaceuticals NV, Sulzer AG
Europe Research Roundup: Cosmo Pharmaceuticals NV, Dormakaba Holding AG, KPN